{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:17:49Z","timestamp":1791562669617,"version":"4.3.4"},"reference-count":395,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministry of Education Youth and Sports of the Czech Republic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["LX22NPO5103"],"award-info":[{"award-number":["LX22NPO5103"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Aspects of Medicine"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.mam.2022.101159","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T05:58:58Z","timestamp":1669701538000},"page":"101159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["Viral proteases as therapeutic targets"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5536-3587","authenticated-orcid":false,"given":"Ta\u0165\u00e1na","family":"Majerov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0695-9266","authenticated-orcid":false,"given":"Jan","family":"Konvalinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mam.2022.101159_bib1","series-title":"Open Science Discovery of Oral Non-covalent SARS-CoV-2 Main Protease Inhibitor Therapeutics","author":"Achdout","year":"2022"},{"key":"10.1016\/j.mam.2022.101159_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105074","article-title":"Targeting the NS2B-NS3 protease of tick-borne encephalitis virus with pan-flaviviral protease inhibitors","volume":"190","author":"Akaberi","year":"2021","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/v11010030","article-title":"Overview of HCV life cycle with a special focus on current and possible future antiviral targets","volume":"11","author":"Alazard-Dany","year":"2019","journal-title":"Viruses"},{"issue":"47","key":"10.1016\/j.mam.2022.101159_bib4","doi-asserted-by":"crossref","first-page":"39470","DOI":"10.1074\/jbc.M112.388678","article-title":"Activity, specificity, and probe design for the smallpox virus protease K7L","volume":"287","author":"Aleshin","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.mam.2022.101159_bib5","first-page":"1729","article-title":"Antitumorigenic action of nelfinavir: effects on multiple myeloma and hematologic malignancies (Review)","volume":"43","author":"Allegra","year":"2020","journal-title":"Oncol. Rep."},{"issue":"5","key":"10.1016\/j.mam.2022.101159_bib6","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jacc.2018.04.083","article-title":"Protease inhibitors and cardiovascular outcomes in patients with HIV and heart failure","volume":"72","author":"Alvi","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"10.1016\/j.mam.2022.101159_bib7","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1128\/JVI.02539-08","article-title":"Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors","volume":"83","author":"Aoki","year":"2009","journal-title":"J. Virol."},{"issue":"24","key":"10.1016\/j.mam.2022.101159_bib8","doi-asserted-by":"crossref","first-page":"13384","DOI":"10.1128\/JVI.07234-11","article-title":"Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1","volume":"86","author":"Aoki","year":"2012","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.mam.2022.101159_bib9","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00134-021-06448-5","article-title":"Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial","volume":"47","author":"Arabi","year":"2021","journal-title":"Intensive Care Med."},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1021\/ml9000276","article-title":"Discovery of narlaprevir (SCH 900518): a potent, second generation HCV NS3 serine protease inhibitor","volume":"1","author":"Arasappan","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.mam.2022.101159_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253364","article-title":"Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies","volume":"16","author":"Armstrong","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2020.11.024","article-title":"Structural insights into SARS-CoV-2 proteins","volume":"433","author":"Arya","year":"2021","journal-title":"J. Mol. Biol."},{"issue":"13","key":"10.1016\/j.mam.2022.101159_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11133838","article-title":"Current effective therapeutics in management of COVID-19","volume":"11","author":"Atluri","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.mam.2022.101159_bib14","article-title":"A real-world study to compare the safety and efficacy of paritaprevir\/ombitasvir\/ritonavir and dasabuvir, with or without ribavirin, in 587 patients with chronic hepatitis C at the fundeni clinical Institute, bucharest, Romania","volume":"28","author":"Bacinschi","year":"2022","journal-title":"Med. Sci. Mon. Int. Med. J. Exp. Clin. Res."},{"issue":"8","key":"10.1016\/j.mam.2022.101159_bib15","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1080\/07391102.2020.1756409","article-title":"Dancing with Trojan horses: an interplay between the extracellular vesicles and viruses","volume":"39","author":"Badierah","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"7","key":"10.1016\/j.mam.2022.101159_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109133","article-title":"Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture","volume":"35","author":"Bafna","year":"2021","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245962","article-title":"A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease","volume":"16","author":"Baker","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.mam.2022.101159_bib18","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.57309","article-title":"SARS-CoV-2 (COVID-19) by the numbers","volume":"9","author":"Bar-On","year":"2020","journal-title":"Elife"},{"issue":"5","key":"10.1016\/j.mam.2022.101159_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19051418","article-title":"The impact of human papilloma viruses, matrix metallo-proteinases and HIV protease inhibitors on the onset and progression of uterine cervix epithelial tumors: a review of preclinical and clinical studies","volume":"19","author":"Barillari","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"4599","key":"10.1016\/j.mam.2022.101159_bib20","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.6189183","article-title":"Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)","volume":"220","author":"Barr\u00e9-Sinoussi","year":"1983","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3851\/IMP1786","article-title":"Lopinavir up-regulates expression of the antiviral protein ribonuclease L in human papillomavirus-positive cervical carcinoma cells","volume":"16","author":"Batman","year":"2011","journal-title":"Antivir. Ther."},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib22","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1128\/CMR.5.2.146","article-title":"Antiviral therapy: current concepts and practices","volume":"5","author":"Bean","year":"1992","journal-title":"Clin. Microbiol. Rev."},{"issue":"12","key":"10.1016\/j.mam.2022.101159_bib23","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.chom.2021.11.010","article-title":"On track to tackle dengue: history and future of NS4B ligands","volume":"29","author":"Behnam","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"7","key":"10.1016\/j.mam.2022.101159_bib24","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1021\/acsptsci.2c00105","article-title":"Corona versus dengue: distinct mechanisms for inhibition of polyprotein processing by antiviral drugs","volume":"5","author":"Behnam","year":"2022","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"6548","key":"10.1016\/j.mam.2022.101159_bib25","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.abf3546","article-title":"Structural basis of ribosomal frameshifting during translation of the SARS-CoV-2 RNA genome","volume":"372","author":"Bhatt","year":"2021","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.mam.2022.101159_bib26","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3390\/toxins7051616","article-title":"Induction of suicidal erythrocyte death by nelfinavir","volume":"7","author":"Bissinger","year":"2015","journal-title":"Toxins"},{"key":"10.1016\/j.mam.2022.101159_bib27","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.20492","article-title":"A transmission-virulence evolutionary trade-off explains attenuation of HIV-1 in Uganda","volume":"5","author":"Blanquart","year":"2016","journal-title":"Elife"},{"issue":"6","key":"10.1016\/j.mam.2022.101159_bib28","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/COH.0b013e328312c392","article-title":"Toxicity of HIV protease inhibitors: clinical considerations","volume":"3","author":"Boesecke","year":"2008","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.mam.2022.101159_bib29","first-page":"1","article-title":"Advances in covalent drug discovery","author":"Boike","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"18","key":"10.1016\/j.mam.2022.101159_bib30","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1021\/jm970873c","article-title":"New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development","volume":"41","author":"Bold","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mam.2022.101159_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2019.107154","article-title":"Understanding of the drug resistance mechanism of hepatitis C virus NS3\/4A to paritaprevir due to D168N\/Y mutations: a molecular dynamics simulation perspective","volume":"83","author":"Boonma","year":"2019","journal-title":"Comput. Biol. Chem."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib32","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1038\/s41467-021-26239-2","article-title":"Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19","volume":"12","author":"Boras","year":"2021","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.mam.2022.101159_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/cells10123383","article-title":"Small extracellular vesicles and COVID19-using the \"trojan horse\" to tackle the giant","volume":"10","author":"Borowiec","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2009.10.002","article-title":"The development of antiretroviral therapy and its impact on the HIV-1\/AIDS pandemic","volume":"85","author":"Broder","year":"2010","journal-title":"Antivir. Res."},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib35","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/bcr2602","article-title":"Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells","volume":"12","author":"Br\u00fcning","year":"2010","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.mam.2022.101159_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.rechem.2020.100094","article-title":"In-silico drug repurposing study: amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex","volume":"3","author":"Buitr\u00f3n-Gonz\u00e1lez","year":"2021","journal-title":"Results Chem"},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010141","article-title":"The changing epidemiology of human monkeypox-A potential threat? A systematic review","volume":"16","author":"Bunge","year":"2022","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"7","key":"10.1016\/j.mam.2022.101159_bib38","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1016\/S2213-2600(22)00192-8","article-title":"The future of Paxlovid for COVID-19","volume":"10","author":"Burki","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"12","key":"10.1016\/j.mam.2022.101159_bib39","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1592\/phco.24.17.1732.52347","article-title":"Atazanavir for the treatment of human immunodeficiency virus infection","volume":"24","author":"Busti","year":"2004","journal-title":"Pharmacotherapy"},{"issue":"7824","key":"10.1016\/j.mam.2022.101159_bib40","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/d41586-020-02544-6","article-title":"The coronavirus is mutating - does it matter?","volume":"585","author":"Callaway","year":"2020","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.mam.2022.101159_bib41","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mam.2022.101159_bib42","article-title":"Virologic and immunologic characterization of COVID-19 recrudescence after nirmatrelvir\/ritonavir treatment","author":"Carlin","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"11","key":"10.1016\/j.mam.2022.101159_bib43","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1177\/1060028018772181","article-title":"Direct-acting antivirals to prevent vertical transmission of viral hepatitis C: when is the optimal time to treat?","volume":"52","author":"Cervino","year":"2018","journal-title":"Ann. Pharmacother."},{"issue":"10","key":"10.1016\/j.mam.2022.101159_bib44","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/jmv.22161","article-title":"Lopinavir\/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways?","volume":"83","author":"Champenois","year":"2011","journal-title":"J. Med. Virol."},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib45","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jmb.2011.03.038","article-title":"Accessory mutations maintain stability in drug-resistant HIV-1 protease","volume":"410","author":"Chang","year":"2011","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib46","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1038\/s41598-019-43554-3","article-title":"Real-world safety and efficacy of paritaprevir\/ritonavir\/ombitasvir plus dasabuvir \u00b1 ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis","volume":"9","author":"Chen","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202100576","article-title":"A patent review on SARS coronavirus main protease (3CL(pro)) inhibitors","volume":"17","author":"Chia","year":"2022","journal-title":"ChemMedChem"},{"issue":"8","key":"10.1016\/j.mam.2022.101159_bib48","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/01.cad.0000224448.08706.76","article-title":"Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1","volume":"17","author":"Chow","year":"2006","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.mam.2022.101159_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2012.10.053","article-title":"Design, synthesis and crystallographic analysis of nitrile-based broad-spectrum peptidomimetic inhibitors for coronavirus 3C-like proteases","volume":"59","author":"Chuck","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.mam.2022.101159_bib50","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/nm1295-1284","article-title":"In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency","volume":"1","author":"Chun","year":"1995","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib51","first-page":"13","article-title":"Protease inhibitors: implications for HIV research and treatment","volume":"2","author":"Churchill","year":"1996","journal-title":"J. Int. Assoc. Phys. AIDS Care"},{"issue":"4761","key":"10.1016\/j.mam.2022.101159_bib52","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1126\/science.2425430","article-title":"Isolation of a new human retrovirus from West African patients with AIDS","volume":"233","author":"Clavel","year":"1986","journal-title":"Science"},{"issue":"40","key":"10.1016\/j.mam.2022.101159_bib53","doi-asserted-by":"crossref","first-page":"10136","DOI":"10.1073\/pnas.1805195115","article-title":"Targeting intramolecular proteinase NS2B\/3 cleavages for trans-dominant inhibition of dengue virus","volume":"115","author":"Constant","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mam.2022.101159_bib54","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/bs.aivir.2018.01.001","article-title":"Hosts and sources of endemic human coronaviruses","volume":"100","author":"Corman","year":"2018","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.mam.2022.101159_bib55","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.2147\/DDDT.S172512","article-title":"Glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy","volume":"13","author":"Cotter","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.mam.2022.101159_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2022.06.011","article-title":"COVID-19 \"Rebound\" associated with nirmatrelvir\/ritonavir pre-hospital therapy","author":"Coulson","year":"2022","journal-title":"J. Infect."},{"issue":"6569","key":"10.1016\/j.mam.2022.101159_bib57","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1126\/science.acx9605","article-title":"Antiviral pills could change pandemic's course","volume":"374","author":"Couzin-Frankel","year":"2021","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib58","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0166-3542(91)90045-S","article-title":"Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase","volume":"16","author":"Craig","year":"1991","journal-title":"Antivir. Res."},{"issue":"11","key":"10.1016\/j.mam.2022.101159_bib59","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1128\/JVI.00201-09","article-title":"Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo","volume":"83","author":"Cuevas","year":"2009","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/d41573-021-00202-8","article-title":"A tale of two antiviral targets - and the COVID-19 drugs that bind them","volume":"21","author":"Cully","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.mam.2022.101159_bib61","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00705-020-04628-0","article-title":"The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century","volume":"165","author":"da Costa","year":"2020","journal-title":"Arch. Virol."},{"issue":"19","key":"10.1016\/j.mam.2022.101159_bib62","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2174\/1568026619666190816101948","article-title":"Virtual screening techniques in drug discovery: review and recent applications","volume":"19","author":"da Silva Rocha","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib63","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1038\/s41467-019-10366-y","article-title":"Sequential LASER ART and CRISPR treatments eliminate HIV-1 in a subset of infected humanized mice","volume":"10","author":"Dash","year":"2019","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.mam.2022.101159_bib64","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1128\/AAC.00055-12","article-title":"Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing","volume":"56","author":"Davis","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5b","key":"10.1016\/j.mam.2022.101159_bib65","first-page":"1023","article-title":"Perspectives for the chemotherapy of AIDS","volume":"7","author":"De Clercq","year":"1987","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib66","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jcv.2004.02.009","article-title":"Antiviral drugs in current clinical use","volume":"30","author":"De Clercq","year":"2004","journal-title":"J. Clin. Virol."},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib67","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"issue":"7","key":"10.1016\/j.mam.2022.101159_bib68","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/01.aids.0000222084.44411.cc","article-title":"Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance","volume":"20","author":"de Mendoza","year":"2006","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.mam.2022.101159_bib69","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.cell.2013.10.034","article-title":"Temporal response of the human virome to immunosuppression and antiviral therapy","volume":"155","author":"De Vlaminck","year":"2013","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.mam.2022.101159_bib70","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","volume":"117","author":"de Wit","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.mam.2022.101159_bib71","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.yjmcc.2010.08.013","article-title":"HIV protease inhibitors elicit volume-sensitive Cl- current in cardiac myocytes via mitochondrial ROS","volume":"49","author":"Deng","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib72","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4161\/rna.8.2.15013","article-title":"Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity","volume":"8","author":"Denison","year":"2011","journal-title":"RNA Biol."},{"key":"10.1016\/j.mam.2022.101159_bib73","series-title":"Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases","first-page":"563","article-title":"46 - antiviral drugs against hepatitis viruses","author":"Dienstag","year":"2015"},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib74","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2005.07.003","article-title":"Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir","volume":"68","author":"Doyon","year":"2005","journal-title":"Antivir. Res."},{"issue":"7","key":"10.1016\/j.mam.2022.101159_bib75","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1021\/jm9805384","article-title":"Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements","volume":"42","author":"Dragovich","year":"1999","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib76","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41385-020-0287-5","article-title":"Seasonal and pandemic influenza: 100 years of progress, still much to learn","volume":"13","author":"Dunning","year":"2020","journal-title":"Mucosal Immunol."},{"issue":"10","key":"10.1016\/j.mam.2022.101159_bib77","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.cmi.2016.08.025","article-title":"Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy","volume":"22","author":"Dustin","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"issue":"52","key":"10.1016\/j.mam.2022.101159_bib78","doi-asserted-by":"crossref","first-page":"23544","DOI":"10.1002\/anie.202010316","article-title":"Allosteric inhibition of the SARS-CoV-2 main protease: insights from mass spectrometry based assays","volume":"59","author":"El-Baba","year":"2020","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"12","key":"10.1016\/j.mam.2022.101159_bib79","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1073\/pnas.74.12.5716","article-title":"Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine","volume":"74","author":"Elion","year":"1977","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"15","key":"10.1016\/j.mam.2022.101159_bib80","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1097\/QAD.0b013e32834b4d48","article-title":"Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine\/tenofovir df in the initial treatment of HIV infection","volume":"25","author":"Elion","year":"2011","journal-title":"Aids"},{"key":"10.1016\/j.mam.2022.101159_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(22)00006-6","article-title":"Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial","author":"Ely","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib82","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nsmb1073","article-title":"Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus","volume":"13","author":"Erbel","year":"2006","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"13","key":"10.1016\/j.mam.2022.101159_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25133093","article-title":"The GABA(B) receptor-structure, ligand binding and drug development","volume":"25","author":"Evenseth","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.mam.2022.101159_bib84","author":"Excision"},{"issue":"5","key":"10.1016\/j.mam.2022.101159_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051065","article-title":"Nelfinavir inhibits the TCF11\/nrf1-mediated proteasome recovery pathway in multiple myeloma","volume":"12","author":"Fassmannov\u00e1","year":"2020","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.mam.2022.101159_bib86","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1345\/aph.1P744","article-title":"Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C","volume":"45","author":"Foote","year":"2011","journal-title":"Ann. Pharmacother."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib87","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1038\/s41467-020-18233-x","article-title":"Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease","volume":"11","author":"Fu","year":"2020","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib88","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/AAC.48.3.791-798.2004","article-title":"Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir","volume":"48","author":"Furfine","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib89","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1128\/AAC.20.4.518","article-title":"Metabolism of acyclovir in virus-infected and uninfected cells","volume":"20","author":"Furman","year":"1981","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.mam.2022.101159_bib90","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/cmdc.201500526","article-title":"Fragment-based protein-protein interaction antagonists of a viral dimeric protease","volume":"11","author":"Gable","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.mam.2022.101159_bib91","first-page":"502","article-title":"Regulation of human T-cell proliferation: T-cell growth factor and isolation of a new class of type-C retroviruses from human T-cells","volume":"26","author":"Gallo","year":"1981","journal-title":"Haematol. Blood Transfus."},{"issue":"4599","key":"10.1016\/j.mam.2022.101159_bib92","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1126\/science.6601823","article-title":"Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS)","volume":"220","author":"Gallo","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.mam.2022.101159_bib93","article-title":"DrugRep: an automatic virtual screening server for drug repurposing","volume":"1\u20139","author":"Gan","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib94","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1053\/j.gastro.2016.07.020","article-title":"High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis","volume":"151","author":"Gane","year":"2016","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.mam.2022.101159_bib95","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1053\/j.gastro.2016.07.038","article-title":"Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with hepatitis C virus genotype 2, 3, 4, or 6 infections in an open-label, phase 2 trial","volume":"151","author":"Gane","year":"2016","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib96","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1053\/j.gastro.2016.05.021","article-title":"Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3\/4A protease inhibitor GS-9857 in treatment-na\u00efve or previously treated patients with hepatitis C virus genotype 1 or 3 infections","volume":"151","author":"Gane","year":"2016","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.mam.2022.101159_bib97","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/jvh.13497","article-title":"Resistance-associated substitutions after sofosbuvir\/velpatasvir\/voxilaprevir triple therapy failure","volume":"28","author":"Garcia-Cehic","year":"2021","journal-title":"J. Viral Hepat."},{"issue":"5","key":"10.1016\/j.mam.2022.101159_bib98","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/1074-5521(95)90050-0","article-title":"Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming","volume":"2","author":"Gehlhaar","year":"1995","journal-title":"Chem. Biol."},{"issue":"7","key":"10.1016\/j.mam.2022.101159_bib99","doi-asserted-by":"crossref","DOI":"10.1038\/nmicrobiol.2016.45","article-title":"Highly heterogeneous mutation rates in the hepatitis C virus genome","volume":"1","author":"Geller","year":"2016","journal-title":"Nat. Microbiol."},{"issue":"9","key":"10.1016\/j.mam.2022.101159_bib100","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01002-20","article-title":"The FDA-approved drug nelfinavir inhibits lytic cell-free but not cell-associated nonlytic transmission of human adenovirus","volume":"64","author":"Georgi","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"24","key":"10.1016\/j.mam.2022.101159_bib101","doi-asserted-by":"crossref","first-page":"7576","DOI":"10.1016\/j.bmc.2007.09.010","article-title":"Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV","volume":"15","author":"Ghosh","year":"2007","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib102","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1021\/ar7001232","article-title":"Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance","volume":"41","author":"Ghosh","year":"2008","journal-title":"Acc. Chem. Res."},{"issue":"11","key":"10.1016\/j.mam.2022.101159_bib103","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1021\/acs.jmedchem.5b01697","article-title":"Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV\/AIDS","volume":"59","author":"Ghosh","year":"2016","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.mam.2022.101159_bib104","doi-asserted-by":"crossref","first-page":"8315","DOI":"10.1021\/acs.jmedchem.5b00258","article-title":"Applications of fluorine in medicinal chemistry","volume":"58","author":"Gillis","year":"2015","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4161\/auto.5224","article-title":"Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy","volume":"4","author":"Gills","year":"2008","journal-title":"Autophagy"},{"issue":"16","key":"10.1016\/j.mam.2022.101159_bib106","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.2165\/00003495-200363160-00003","volume":"63","author":"Goldsmith","year":"2003","journal-title":"Atazanavir. Drugs"},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib107","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jhep.2014.08.052","article-title":"Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET","volume":"62","author":"Gordon","year":"2015","journal-title":"J. Hepatol."},{"issue":"22","key":"10.1016\/j.mam.2022.101159_bib108","doi-asserted-by":"crossref","first-page":"7866","DOI":"10.1039\/D0SC06805E","article-title":"Accelerating high-throughput virtual screening through molecular pool-based active learning","volume":"12","author":"Graff","year":"2021","journal-title":"Chem. Sci."},{"issue":"17","key":"10.1016\/j.mam.2022.101159_bib109","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1042\/CS20160786","article-title":"The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review","volume":"131","author":"Graham","year":"2017","journal-title":"Clin. Sci. (Lond.)"},{"issue":"2039","key":"10.1016\/j.mam.2022.101159_bib110","article-title":"Human endogenous retroviruses are ancient acquired elements still shaping innate immune responses","volume":"9","author":"Grandi","year":"2018","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.mam.2022.101159_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101972","article-title":"Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants","volume":"298","author":"Greasley","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mam.2022.101159_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109775","article-title":"Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome inhibitors","volume":"75","author":"Gu","year":"2020","journal-title":"Cell. Signal."},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib113","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1128\/jvi.69.4.2534-2539.1995","article-title":"NS3-4A of hepatitis C virus is a chymotrypsin-like protease","volume":"69","author":"Hahm","year":"1995","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.mam.2022.101159_bib114","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1007\/s00204-020-02936-7","article-title":"Inhibition and induction of CYP enzymes in humans: an update","volume":"94","author":"Hakkola","year":"2020","journal-title":"Arch. Toxicol."},{"issue":"15","key":"10.1016\/j.mam.2022.101159_bib115","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"Pt 4","key":"10.1016\/j.mam.2022.101159_bib116","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1099\/0022-1317-76-4-985","article-title":"Identification of the protease domain in NS3 of hepatitis C virus","volume":"76","author":"Han","year":"1995","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.mam.2022.101159_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104574","article-title":"Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-na\u00efve subjects","volume":"170","author":"Han","year":"2019","journal-title":"Antivir. Res."},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib118","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1021\/acs.jmedchem.1c00598","article-title":"Structure-based optimization of ml300-derived, noncovalent inhibitors targeting the severe acute respiratory syndrome coronavirus 3CL protease (SARS-CoV-2 3CL(pro))","volume":"65","author":"Han","year":"2022","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib119","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1021\/ml300017p","article-title":"Discovery of MK-5172, a macrocyclic hepatitis C virus NS3\/4a protease inhibitor","volume":"3","author":"Harper","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"issue":"33","key":"10.1016\/j.mam.2022.101159_bib120","doi-asserted-by":"crossref","first-page":"12234","DOI":"10.1073\/pnas.1400027111","article-title":"Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir","volume":"111","author":"Hayashi","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.mam.2022.101159_bib121","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40265-018-0895-5","article-title":"Sofosbuvir\/velpatasvir\/voxilaprevir: a review in chronic hepatitis C","volume":"78","author":"Heo","year":"2018","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib122","first-page":"217","article-title":"Antiviral agents","volume":"58","author":"Hermans","year":"1983","journal-title":"Mayo Clin. Proc."},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib123","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1128\/JVI.73.3.1902-1908.1999","article-title":"Human immunodeficiency virus type 1 protease triggers a myristoyl switch that modulates membrane binding of Pr55(gag) and p17MA","volume":"73","author":"Hermida-Matsumoto","year":"1999","journal-title":"J. Virol."},{"issue":"10319","key":"10.1016\/j.mam.2022.101159_bib124","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0140-6736(21)02657-X","article-title":"Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management","volume":"399","author":"Heskin","year":"2022","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.mam.2022.101159_bib125","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/liv.13638","article-title":"Treatment of hepatitis C: results in real life","volume":"38","author":"H\u00e9zode","year":"2018","journal-title":"Liver Int."},{"key":"10.1016\/j.mam.2022.101159_bib126","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-981-10-8727-1_10","article-title":"The structure of the Zika virus protease, NS2B\/NS3(pro)","volume":"1062","author":"Hilgenfeld","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"issue":"7859","key":"10.1016\/j.mam.2022.101159_bib127","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41586-021-03511-5","article-title":"Unconventional viral gene expression mechanisms as therapeutic targets","volume":"593","author":"Ho","year":"2021","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.mam.2022.101159_bib128","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib129","first-page":"22","article-title":"The discovery and development of boceprevir: a novel, first-generation inhibitor of the hepatitis C virus NS3\/4A serine protease","volume":"1","author":"Howe","year":"2013","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib130","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41598-018-36730-4","article-title":"Targeting HIV-1 protease autoprocessing for high-throughput drug discovery and drug resistance assessment","volume":"9","author":"Huang","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mam.2022.101159_bib131","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijid.2020.01.009","article-title":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China","volume":"91","author":"Hui","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib132","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28638-w","article-title":"Inhibition of the precursor and mature forms of HIV-1 protease as a tool for drug evaluation","volume":"8","author":"Humpol\u00ed\u010dkov\u00e1","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-021-00784-w","article-title":"Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection","volume":"29","author":"Hwang","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.mam.2022.101159_bib134","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","author":"Iketani","year":"2022","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.mam.2022.101159_bib135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010644","article-title":"Identification of NS2 determinants stimulating intrinsic HCV NS2 protease activity","volume":"18","author":"Isken","year":"2022","journal-title":"PLoS Pathog."},{"issue":"6153","key":"10.1016\/j.mam.2022.101159_bib136","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/331280a0","article-title":"Characterization of ribosomal frameshifting in HIV-1 gag-pol expression","volume":"331","author":"Jacks","year":"1988","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib137","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm301580n","volume":"56","author":"Jacobs","year":"2013","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib138","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0042-6822(95)80069-7","article-title":"Characterization of human immunodeficiency virus type 1 mutantswith decreased sensitivity to proteinase inhibitor Ro 31-8959","volume":"206","author":"Jacobsen","year":"1995","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib139","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 Weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.mam.2022.101159_bib140","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1053\/j.gastro.2017.01.050","article-title":"Safety and efficacy of elbasvir\/grazoprevir in patients with hepatitis C virus infection and compensated cirrhosis: an integrated analysis","volume":"152","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"issue":"237","key":"10.1016\/j.mam.2022.101159_bib141","first-page":"1","article-title":"Saquinavir (Invirase): first protease inhibitor approved--reimbursement, information hotline numbers","author":"James","year":"1995","journal-title":"AIDS Treat. News"},{"key":"10.1016\/j.mam.2022.101159_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105430","article-title":"Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice","volume":"208","author":"Jeong","year":"2022","journal-title":"Antivir. Res."},{"issue":"12","key":"10.1016\/j.mam.2022.101159_bib143","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.1128\/AAC.01578-13","article-title":"In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir","volume":"57","author":"Jiang","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7811","key":"10.1016\/j.mam.2022.101159_bib144","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib145","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1742-4690-7-89","article-title":"Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease","volume":"7","author":"Jochmans","year":"2010","journal-title":"Retrovirology"},{"key":"10.1016\/j.mam.2022.101159_bib146","article-title":"The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir","author":"Jochmans","year":"2022","journal-title":"bioRxiv"},{"issue":"9","key":"10.1016\/j.mam.2022.101159_bib147","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"24","key":"10.1016\/j.mam.2022.101159_bib148","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1021\/jm9704098","article-title":"Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease","volume":"40","author":"Kaldor","year":"1997","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.mam.2022.101159_bib149","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1128\/JVI.03790-13","article-title":"Nelfinavir inhibits maturation and export of herpes simplex virus 1","volume":"88","author":"Kalu","year":"2014","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.mam.2022.101159_bib150","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.tim.2017.07.001","article-title":"Zika virus protease: an antiviral drug target","volume":"25","author":"Kang","year":"2017","journal-title":"Trends Microbiol."},{"issue":"10","key":"10.1016\/j.mam.2022.101159_bib151","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1073\/pnas.88.10.4528","article-title":"Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments","volume":"88","author":"Kaplan","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7881","key":"10.1016\/j.mam.2022.101159_bib152","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41586-021-03990-6","article-title":"A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction","volume":"598","author":"Kaptein","year":"2021","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib153","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s10593-021-02912-8","article-title":"Antiviral nucleoside analogs","volume":"57","author":"Kataev","year":"2021","journal-title":"Chem. Heterocycl. Compd."},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib154","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000149733","article-title":"Maturation of human immunodeficiency virus, strain LAV, in vitro","volume":"27","author":"Katsumoto","year":"1987","journal-title":"Intervirology"},{"key":"10.1016\/j.mam.2022.101159_bib155","doi-asserted-by":"crossref","DOI":"10.1177\/20587384211002621","article-title":"A review: mechanism of action of antiviral drugs","volume":"35","author":"Kausar","year":"2021","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"7","key":"10.1016\/j.mam.2022.101159_bib156","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1038\/cddis.2012.87","article-title":"Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells","volume":"3","author":"Kawabata","year":"2012","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.mam.2022.101159_bib157","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40265-016-0558-3","article-title":"Elbasvir\/grazoprevir: first global approval","volume":"76","author":"Keating","year":"2016","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.mam.2022.101159_bib158","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1073\/pnas.92.7.2484","article-title":"ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans","volume":"92","author":"Kempf","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib159","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1128\/AAC.41.3.654","article-title":"Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir","volume":"41","author":"Kempf","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"issue":"16","key":"10.1016\/j.mam.2022.101159_bib160","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1128\/JVI.75.16.7462-7469.2001","article-title":"Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients","volume":"75","author":"Kempf","year":"2001","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib161","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1021\/bi027045s","article-title":"Structural and biochemical studies of inhibitor binding to human cytomegalovirus protease","volume":"42","author":"Khayat","year":"2003","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib162","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1021\/ja00108a056","article-title":"Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme","volume":"117","author":"Kim","year":"1995","journal-title":"J. Am. Chem. Soc."},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib163","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0092-8674(00)81351-3","article-title":"Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide","volume":"87","author":"Kim","year":"1996","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.mam.2022.101159_bib164","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106275","article-title":"Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2","volume":"39","author":"Klemm","year":"2020","journal-title":"EMBO J."},{"issue":"10","key":"10.1016\/j.mam.2022.101159_bib165","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1128\/AAC.47.10.3123-3129.2003","article-title":"Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro","volume":"47","author":"Koh","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"13","key":"10.1016\/j.mam.2022.101159_bib166","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1073\/pnas.85.13.4686","article-title":"Active human immunodeficiency virus protease is required for viral infectivity","volume":"85","author":"Kohl","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.mam.2022.101159_bib167","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1128\/jvi.69.11.7180-7186.1995","article-title":"An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity","volume":"69","author":"Konvalinka","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.mam.2022.101159_bib168","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.virol.2015.03.021","article-title":"Retroviral proteases and their roles in virion maturation","volume":"479\u2013480","author":"Konvalinka","year":"2015","journal-title":"Virology"},{"issue":"7","key":"10.1016\/j.mam.2022.101159_bib169","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2337\/diabetes.52.7.1695","article-title":"HIV protease inhibitors acutely impair glucose-stimulated insulin release","volume":"52","author":"Koster","year":"2003","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib170","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jmb.2007.09.083","article-title":"Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants","volume":"374","author":"Ko\u017e\u00ed\u0161ek","year":"2007","journal-title":"J. Mol. Biol."},{"issue":"8","key":"10.1016\/j.mam.2022.101159_bib171","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1128\/AAC.00465-12","article-title":"Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease","volume":"56","author":"Koz\u00edsek","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.mam.2022.101159_bib172","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1111\/febs.12743","article-title":"Thermodynamic and structural analysis of HIV protease resistance to darunavir - analysis of heavily mutated patient-derived HIV-1 proteases","volume":"281","author":"Ko\u017e\u00ed\u0161ek","year":"2014","journal-title":"FEBS J."},{"issue":"8","key":"10.1016\/j.mam.2022.101159_bib173","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1073\/pnas.88.8.3213","article-title":"Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity","volume":"88","author":"Kr\u00e4usslich","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.mam.2022.101159_bib174","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1128\/AAC.00998-15","article-title":"Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir","volume":"59","author":"Krishnan","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib175","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0022-3565(25)12840-1","article-title":"Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes","volume":"277","author":"Kumar","year":"1996","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"23","key":"10.1016\/j.mam.2022.101159_bib176","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202101113","article-title":"Broad-spectrum antiviral peptides and polymers","volume":"10","author":"Kuroki","year":"2021","journal-title":"Adv. Healthc. Mater."},{"issue":"1\u20132","key":"10.1016\/j.mam.2022.101159_bib177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(98)00043-6","article-title":"Hepatitis C virus NS3\/4A protease","volume":"40","author":"Kwong","year":"1998","journal-title":"Antivir. Res."},{"issue":"11","key":"10.1016\/j.mam.2022.101159_bib178","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nbt.2020","article-title":"Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus","volume":"29","author":"Kwong","year":"2011","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"10.1016\/j.mam.2022.101159_bib179","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40265-022-01692-5","article-title":"Nirmatrelvir plus ritonavir: first approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"issue":"6822","key":"10.1016\/j.mam.2022.101159_bib180","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/35057062","article-title":"Initial sequencing and analysis of the human genome","volume":"409","author":"Lander","year":"2001","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib181","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2013.02.009","article-title":"A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450\/r, ABT-072) and ribavirin in IL28B C\/C patients with chronic hepatitis C genotype 1","volume":"59","author":"Lawitz","year":"2013","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib182","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1128\/AAC.02264-15","article-title":"Potent antiviral activities of the direct-acting antivirals ABT-493 and ABT-530 with three-day monotherapy for hepatitis C virus genotype 1 infection","volume":"60","author":"Lawitz","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.mam.2022.101159_bib183","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1053\/j.gastro.2016.07.039","article-title":"Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with genotype 1 hepatitis C virus infection in an open-label, phase 2 trial","volume":"151","author":"Lawitz","year":"2016","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.mam.2022.101159_bib184","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/hep.29130","article-title":"Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus","volume":"65","author":"Lawitz","year":"2017","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.mam.2022.101159_bib185","doi-asserted-by":"crossref","first-page":"F45","DOI":"10.1097\/00002030-199807000-00002","article-title":"Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma","volume":"12","author":"Lebb\u00e9","year":"1998","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib186","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1186\/s13054-020-03117-9","article-title":"Comparison of hydroxychloroquine, lopinavir\/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis","volume":"24","author":"Lecronier","year":"2020","journal-title":"Crit. Care"},{"issue":"5","key":"10.1016\/j.mam.2022.101159_bib187","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jmb.2011.06.032","article-title":"Enzyme inhibition by allosteric capture of an inactive conformation","volume":"411","author":"Lee","year":"2011","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib188","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1038\/s41467-020-19662-4","article-title":"Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site","volume":"11","author":"Lee","year":"2020","journal-title":"Nat. Commun."},{"issue":"6298","key":"10.1016\/j.mam.2022.101159_bib189","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1126\/science.aag2419","article-title":"Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor","volume":"353","author":"Lei","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.mam.2022.101159_bib190","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.antiviral.2017.11.001","article-title":"Nsp3 of coronaviruses: structures and functions of a large multi-domain protein","volume":"149","author":"Lei","year":"2018","journal-title":"Antivir. Res."},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib191","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3390\/v13030520","article-title":"Hepatitis C viral replication complex","volume":"13","author":"Li","year":"2021","journal-title":"Viruses"},{"issue":"8","key":"10.1016\/j.mam.2022.101159_bib192","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41579-021-00536-5","article-title":"The human virome: assembly, composition and host interactions","volume":"19","author":"Liang","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"issue":"17","key":"10.1016\/j.mam.2022.101159_bib193","doi-asserted-by":"crossref","first-page":"17508","DOI":"10.1074\/jbc.M313020200","article-title":"In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms","volume":"279","author":"Lin","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib194","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1128\/AAC.01058-08","article-title":"In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor","volume":"53","author":"Lin","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib195","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.xphs.2016.10.007","article-title":"Pharmacokinetics, safety, and tolerability of single and multiple doses of ABT-493: a first-in-human study","volume":"106","author":"Lin","year":"2017","journal-title":"J. Pharmacol. Sci."},{"issue":"6559","key":"10.1016\/j.mam.2022.101159_bib196","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1126\/science.abi9310","article-title":"Structural basis of mismatch recognition by a SARS-CoV-2 proofreading enzyme","volume":"373","author":"Liu","year":"2021","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.mam.2022.101159_bib197","first-page":"5747","article-title":"Impact of antiretroviral drugs on PD-L1 expression and copy number gains with clinical outcomes in HIV-positive and -negative locally advanced cervical cancers","volume":"18","author":"Loharamtaweethong","year":"2019","journal-title":"Oncol. Lett."},{"issue":"2 Suppl. l","key":"10.1016\/j.mam.2022.101159_bib198","first-page":"11","article-title":"Processing pathways of the hepatitis C virus proteins","volume":"24","author":"Lohmann","year":"1996","journal-title":"J. Hepatol."},{"issue":"22","key":"10.1016\/j.mam.2022.101159_bib199","doi-asserted-by":"crossref","first-page":"9072","DOI":"10.1073\/pnas.1102278108","article-title":"Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors","volume":"108","author":"Louis","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib200","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0092-8674(00)81350-1","article-title":"The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site","volume":"87","author":"Love","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.mam.2022.101159_bib201","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.antiviral.2015.03.014","article-title":"The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development","volume":"118","author":"Luo","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.mam.2022.101159_bib202","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.819165","article-title":"Targeting SARS-CoV-2 proteases for COVID-19 antiviral development","volume":"9","author":"Lv","year":"2022","journal-title":"Front. Chem."},{"issue":"8","key":"10.1016\/j.mam.2022.101159_bib203","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res."},{"issue":"Pt 3","key":"10.1016\/j.mam.2022.101159_bib204","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1107\/S0909049507064229","article-title":"Key steps in the structure-based optimization of the hepatitis C virus NS3\/4A protease inhibitor SCH5 03034","volume":"15","author":"Madison","year":"2008","journal-title":"J. Synchrotron Radiat."},{"key":"10.1016\/j.mam.2022.101159_bib205","series-title":"Encyclopedia of Biological Chemistry III","first-page":"264","article-title":"Enyzmes | HIV protease","author":"Majerov\u00e1","year":"2021"},{"issue":"10","key":"10.1016\/j.mam.2022.101159_bib206","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.3390\/v13101981","article-title":"Precursors of viral proteases as distinct drug targets","volume":"13","author":"Majerov\u00e1","year":"2021","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib207","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1135\/cccc2009087","article-title":"Therapeutic targets for influenza-Perspectives in drug development","volume":"75","author":"Majerov\u00e1","year":"2010","journal-title":"Collect. Czech Chem. Commun."},{"key":"10.1016\/j.mam.2022.101159_bib208","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.biochi.2019.05.004","article-title":"Exploiting the unique features of Zika and Dengue proteases for inhibitor design","volume":"166","author":"Majerov\u00e1","year":"2019","journal-title":"Biochimie"},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib209","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcv.2006.01.014","article-title":"Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants","volume":"36","author":"Majerov\u00e1-Uhl\u00edkov\u00e1","year":"2006","journal-title":"J. Clin. Virol."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib210","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.1038\/s41467-020-19821-7","article-title":"CRISPR based editing of SIV proviral DNA in ART treated non-human primates","volume":"11","author":"Mancuso","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib211","article-title":"Hepatitis C virus infection","volume":"3","author":"Manns","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib212","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jmv.20140","article-title":"Resistance profiles observed in virological failures after 24 weeks of amprenavir\/ritonavir containing regimen in protease inhibitor experienced patients","volume":"74","author":"Marcelin","year":"2004","journal-title":"J. Med. Virol."},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib213","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2010.10.046","article-title":"Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C","volume":"140","author":"Marcellin","year":"2011","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.mam.2022.101159_bib214","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40265-018-0960-0","article-title":"Danoprevir: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"issue":"6 Pt B","key":"10.1016\/j.mam.2022.101159_bib215","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3851\/IMP2424","article-title":"The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir","volume":"17","author":"Marks","year":"2012","journal-title":"Antivir. Ther."},{"issue":"5","key":"10.1016\/j.mam.2022.101159_bib216","doi-asserted-by":"crossref","first-page":"744","DOI":"10.7326\/M22-0281","article-title":"Prescribing nirmatrelvir-ritonavir: how to recognize and manage drug-drug interactions","volume":"175","author":"Marzolini","year":"2022","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib217","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/clpt.2009.228","article-title":"Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity","volume":"87","author":"Mathias","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"issue":"23","key":"10.1016\/j.mam.2022.101159_bib218","doi-asserted-by":"crossref","first-page":"13722","DOI":"10.1128\/JVI.02271-14","article-title":"Induced maturation of human immunodeficiency virus","volume":"88","author":"Mattei","year":"2014","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib219","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00172-20","article-title":"Avoiding drug resistance by substrate envelope-guided design: toward potent and robust HCV NS3\/4A protease inhibitors","volume":"11","author":"Matthew","year":"2020","journal-title":"mBio"},{"issue":"6","key":"10.1016\/j.mam.2022.101159_bib220","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1021\/acs.chemrev.0c00648","article-title":"Drug design strategies to avoid resistance in direct-acting antivirals and beyond","volume":"121","author":"Matthew","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.mam.2022.101159_bib221","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/0002-9394(63)90006-0","article-title":"Treatment of herpes keratitis with 5-iodo-2-deoxyuridine (IDU). A clinical evaluation of 1,500 cases","volume":"56","author":"Maxwell","year":"1963","journal-title":"Am. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib222","first-page":"297","article-title":"Emerging infectious diseases","volume":"54","author":"McArthur","year":"2019","journal-title":"Nurs. Clin."},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib223","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41591-021-01282-0","article-title":"Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases","volume":"27","author":"Meganck","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.mam.2022.101159_bib224","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijid.2021.02.092","article-title":"A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: a real-world analysis","volume":"106","author":"Mehta","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.mam.2022.101159_bib225","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2217\/fmb-2018-0233","article-title":"Glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C virus infection","volume":"14","author":"Mensa","year":"2019","journal-title":"Future Microbiol."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib226","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1038\/s41598-022-07867-0","article-title":"An intra-cytoplasmic route for SARS-CoV-2 transmission unveiled by Helium-ion microscopy","volume":"12","author":"Merolli","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mam.2022.101159_bib227","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.2147\/DDDT.S254754","article-title":"Danoprevir for the treatment of hepatitis C virus infection: design, development, and place in therapy","volume":"14","author":"Miao","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"issue":"11","key":"10.1016\/j.mam.2022.101159_bib228","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/ajhp\/56.11.1057","article-title":"Amprenavir approved for HIV treatment","volume":"56","author":"Miller","year":"1999","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"20","key":"10.1016\/j.mam.2022.101159_bib229","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1073\/pnas.82.20.7096","article-title":"3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III\/lymphadenopathy-associated virus in vitro","volume":"82","author":"Mitsuya","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib230","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s42003-020-01577-x","article-title":"Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents","volume":"4","author":"Mody","year":"2021","journal-title":"Commun. Biol."},{"issue":"5","key":"10.1016\/j.mam.2022.101159_bib231","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02447-21","article-title":"HIV-1 genomes are enriched in memory CD4(+) T-cells with short half-lives","volume":"12","author":"Morcilla","year":"2021","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib232","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/187231207779814256","article-title":"Drug interactions of tipranavir, a new HIV protease inhibitor","volume":"1","author":"Morello","year":"2007","journal-title":"Drug Metabol. Lett."},{"issue":"48","key":"10.1016\/j.mam.2022.101159_bib233","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1039\/D1CC00050K","article-title":"Discovery of SARS-CoV-2 main protease inhibitors using a synthesis-directed de novo design model","volume":"57","author":"Morris","year":"2021","journal-title":"Chem. Commun."},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib234","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1086\/314668","article-title":"Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team","volume":"179","author":"Murphy","year":"1999","journal-title":"J. Infect. Dis."},{"issue":"10","key":"10.1016\/j.mam.2022.101159_bib235","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1128\/JVI.02531-09","article-title":"Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance","volume":"84","author":"Nalam","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.mam.2022.101159_bib236","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.imlet.2021.01.001","article-title":"Immune reactivity during COVID-19: implications for treatment","volume":"231","author":"Napoli","year":"2021","journal-title":"Immunol. Lett."},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib237","first-page":"101","article-title":"Drug interactions with cobicistat- or ritonavir-boosted elvitegravir","volume":"18","author":"Nguyen","year":"2016","journal-title":"AIDS Rev."},{"issue":"5","key":"10.1016\/j.mam.2022.101159_bib238","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1021\/acs.jmedchem.0c02070","article-title":"Synthesis, structure-activity relationships, and antiviral activity of allosteric inhibitors of flavivirus NS2B-NS3 protease","volume":"64","author":"Nie","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib239","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1371\/journal.pmed.0040036","article-title":"A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism","volume":"4","author":"Nijhuis","year":"2007","journal-title":"PLoS Med."},{"key":"10.1016\/j.mam.2022.101159_bib240","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/978-3-540-79086-0_11","article-title":"Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases","volume":"189","author":"Nijhuis","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib241","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1021\/ar700109k","article-title":"Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection","volume":"41","author":"Njoroge","year":"2008","journal-title":"Acc. Chem. Res."},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib242","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1039\/D0MD00367K","article-title":"Repurposing the HCV NS3\u20134A protease drug boceprevir as COVID-19 therapeutics","volume":"12","author":"Oerlemans","year":"2021","journal-title":"RSC Med. Chem."},{"issue":"8","key":"10.1016\/j.mam.2022.101159_bib243","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.21873\/anticanres.12754","article-title":"Nelfinavir induces endoplasmic reticulum stress and sensitizes renal cancer cells to TRAIL","volume":"38","author":"Okubo","year":"2018","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib244","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41467-021-21060-3","article-title":"Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors","volume":"12","author":"Osipiuk","year":"2021","journal-title":"Nat. Commun."},{"issue":"6575","key":"10.1016\/j.mam.2022.101159_bib245","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib246","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109892","article-title":"Mechanistic insights into COVID-19 by global analysis of the SARS-CoV-2 3CL(pro) substrate degradome","volume":"37","author":"Pablos","year":"2021","journal-title":"Cell Rep."},{"issue":"22","key":"10.1016\/j.mam.2022.101159_bib247","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225702","article-title":"Kaposi's sarcoma in virally suppressed people living with HIV: an emerging condition","volume":"13","author":"Palich","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib248","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/2040622310384308","article-title":"Pegylated interferon and ribavirin treatment for hepatitis C virus infection","volume":"2","author":"Palumbo","year":"2011","journal-title":"Ther. Adv. Chronic. Dis."},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib249","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032845","article-title":"Placement of leucine zipper motifs at the carboxyl terminus of HIV-1 protease significantly reduces virion production","volume":"7","author":"Pan","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.mam.2022.101159_bib250","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1086\/381972","article-title":"Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections","volume":"38","author":"Pankey","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.mam.2022.101159_bib251","author":"Pardesbio"},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib252","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.antiviral.2009.09.015","article-title":"Clinical management of HIV-1 resistance","volume":"85","author":"Paredes","year":"2010","journal-title":"Antivir. Res."},{"issue":"16","key":"10.1016\/j.mam.2022.101159_bib253","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1021\/acs.biochem.6b00012","article-title":"Binding of clinical inhibitors to a model precursor of a rationally selected multidrug resistant HIV-1 protease is significantly weaker than that to the released mature enzyme","volume":"55","author":"Park","year":"2016","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib254","doi-asserted-by":"crossref","first-page":"440","DOI":"10.5009\/gnl19393","article-title":"Real-life effectiveness and safety of glecaprevir\/pibrentasvir for Korean patients with chronic hepatitis C at a single institution","volume":"15","author":"Park","year":"2021","journal-title":"Gut Liver."},{"issue":"10","key":"10.1016\/j.mam.2022.101159_bib255","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1128\/AAC.42.10.2637","article-title":"Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir","volume":"42","author":"Patick","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl. 11","key":"10.1016\/j.mam.2022.101159_bib256","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12859-018-2331-y","article-title":"Analysis of drug resistance in HIV protease","volume":"19","author":"Pawar","year":"2018","journal-title":"BMC bioinform."},{"key":"10.1016\/j.mam.2022.101159_bib257","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/B978-0-12-803109-4.00010-6","article-title":"Introduction to RNA viruses","author":"Payne","year":"2017","journal-title":"Viruses"},{"issue":"22","key":"10.1016\/j.mam.2022.101159_bib258","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1016\/j.bmcl.2003.08.050","article-title":"Inhibitors of hepatitis C virus NS3.4A protease 1. Non-charged tetrapeptide variants","volume":"13","author":"Perni","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.mam.2022.101159_bib259","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.bmcl.2004.01.078","article-title":"Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants","volume":"14","author":"Perni","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.mam.2022.101159_bib260","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.bmcl.2004.01.022","article-title":"Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization","volume":"14","author":"Perni","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"12","key":"10.1016\/j.mam.2022.101159_bib261","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1016\/j.bmcl.2007.03.090","article-title":"Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics","volume":"17","author":"Perni","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib262","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1128\/JVI.77.1.366-374.2003","article-title":"The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage","volume":"77","author":"Pettit","year":"2003","journal-title":"J. Virol."},{"issue":"16","key":"10.1016\/j.mam.2022.101159_bib263","doi-asserted-by":"crossref","first-page":"8477","DOI":"10.1128\/JVI.78.16.8477-8485.2004","article-title":"Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism","volume":"78","author":"Pettit","year":"2004","journal-title":"J. Virol."},{"issue":"16","key":"10.1016\/j.mam.2022.101159_bib264","doi-asserted-by":"crossref","first-page":"10601","DOI":"10.1128\/JVI.79.16.10601-10607.2005","article-title":"Ordered processing of the human immunodeficiency virus type 1 GagPol precursor is influenced by the context of the embedded viral protease","volume":"79","author":"Pettit","year":"2005","journal-title":"J. Virol."},{"issue":"144","key":"10.1016\/j.mam.2022.101159_bib265","article-title":"Omicron entry route","volume":"22","author":"Pia","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.mam.2022.101159_bib266","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41564-020-0714-0","article-title":"The continued threat of emerging flaviviruses","volume":"5","author":"Pierson","year":"2020","journal-title":"Nat. Microbiol."},{"issue":"9","key":"10.1016\/j.mam.2022.101159_bib267","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1517\/13543784.11.9.1295","article-title":"Atazanavir: a novel HIV-1 protease inhibitor","volume":"11","author":"Piliero","year":"2002","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib268","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3390\/v1031209","article-title":"Current and novel inhibitors of HIV protease","volume":"1","author":"Pokorn\u00e1","year":"2009","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/j.mam.2022.101159_bib269","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/s41435-019-0066-z","article-title":"The remarkable history of the hepatitis C virus","volume":"20","author":"Pol","year":"2019","journal-title":"Gene Immun."},{"issue":"4882","key":"10.1016\/j.mam.2022.101159_bib270","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.2460924","article-title":"Fidelity of HIV-1 reverse transcriptase","volume":"242","author":"Preston","year":"1988","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib271","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/cbdd.14057","article-title":"Machine learning approaches and their applications in drug discovery and design","volume":"100","author":"Priya","year":"2022","journal-title":"Chem. Biol. Drug Des."},{"issue":"7","key":"10.1016\/j.mam.2022.101159_bib272","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10822-022-00460-7","article-title":"Ligand-based and structure-based studies to develop predictive models for SARS-CoV-2 main protease inhibitors through the 3d-qsar.com portal","volume":"36","author":"Proia","year":"2022","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"10","key":"10.1016\/j.mam.2022.101159_bib273","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1021\/jm060173k","volume":"50","author":"Prongay","year":"2007","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib274","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0006-3002(59)90597-9","article-title":"Synthesis and biological activities of iododeoxyuridine, an analog of thymidine","volume":"32","author":"Prusoff","year":"1959","journal-title":"Biochim. Biophys. Acta"},{"issue":"10","key":"10.1016\/j.mam.2022.101159_bib275","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/BF03184203","article-title":"A complete sequence and comparative analysis of a SARS-associated virus (Isolate BJ01)","volume":"48","author":"Qin","year":"2003","journal-title":"Chin. Sci. Bull."},{"issue":"17","key":"10.1016\/j.mam.2022.101159_bib276","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1016\/j.bmcl.2008.07.088","article-title":"Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3\/4A protease leading to the discovery of TMC435350","volume":"18","author":"Raboisson","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib277","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/QAI.0000000000000959","article-title":"Pharmacokinetics of Co-formulated elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate after switch from efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in healthy subjects","volume":"72","author":"Ramanathan","year":"2016","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"42","key":"10.1016\/j.mam.2022.101159_bib278","doi-asserted-by":"crossref","first-page":"16119","DOI":"10.1073\/pnas.0805240105","article-title":"A noncovalent class of papain-like protease\/deubiquitinase inhibitors blocks SARS virus replication","volume":"105","author":"Ratia","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib279","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1053\/j.gastro.2009.10.033","article-title":"Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients","volume":"138","author":"Reesink","year":"2010","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.mam.2022.101159_bib280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002881","article-title":"Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate","volume":"8","author":"Ribeiro","year":"2012","journal-title":"PLoS Pathog."},{"issue":"9","key":"10.1016\/j.mam.2022.101159_bib281","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2165\/00003088-200746090-00002","article-title":"Clinical pharmacokinetics of darunavir","volume":"46","author":"Rittweger","year":"2007","journal-title":"Clin. Pharmacokinet."},{"issue":"4882","key":"10.1016\/j.mam.2022.101159_bib282","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1126\/science.2460925","article-title":"The accuracy of reverse transcriptase from HIV-1","volume":"242","author":"Roberts","year":"1988","journal-title":"Science"},{"issue":"4953","key":"10.1016\/j.mam.2022.101159_bib283","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1126\/science.2183354","article-title":"Rational design of peptide-based HIV proteinase inhibitors","volume":"248","author":"Roberts","year":"1990","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.mam.2022.101159_bib284","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1021\/ja01071a055","article-title":"The synthesis of 2\u2032,3\u2032-dideoxyadenosine from 2\u2032-deoxyadenosine","volume":"86","author":"Robins","year":"1964","journal-title":"J. Am. Chem. Soc."},{"issue":"8","key":"10.1016\/j.mam.2022.101159_bib285","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/jvh.12527","article-title":"GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study","volume":"23","author":"Rodriguez-Torres","year":"2016","journal-title":"J. Viral Hepat."},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib286","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1006\/jmbi.2001.5055","article-title":"Recent advances in the molecular biology of hepatitis C virus","volume":"313","author":"Rosenberg","year":"2001","journal-title":"J. Mol. Biol."},{"issue":"5","key":"10.1016\/j.mam.2022.101159_bib287","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1021\/jm401507s","article-title":"Discovery and development of simeprevir (TMC435), a HCV NS3\/4A protease inhibitor","volume":"57","author":"Rosenquist","year":"2014","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.mam.2022.101159_bib288","first-page":"2281","article-title":"Baricitinib is first approved COVID-19 immunomodulatory treatment","volume":"327","author":"Rubin","year":"2022","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.mam.2022.101159_bib289","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1001\/jama.2022.9925","article-title":"From positive to negative to positive again-the mystery of why COVID-19 rebounds in some patients who take Paxlovid","volume":"327","author":"Rubin","year":"2022","journal-title":"JAMA"},{"issue":"42","key":"10.1016\/j.mam.2022.101159_bib290","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd4596","article-title":"Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti-COVID-19 drug design","volume":"6","author":"Rut","year":"2020","journal-title":"Sci. Adv."},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib291","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41589-020-00689-z","article-title":"SARS-CoV-2 M(pro) inhibitors and activity-based probes for patient-sample imaging","volume":"17","author":"Rut","year":"2021","journal-title":"Nat. Chem. Biol."},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib292","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/liv.13033","article-title":"Cost-effectiveness of ombitasvir\/paritaprevir\/ritonavir, Dasabuvir+Ribavirin for US post-liver transplant recurrent genotype 1 HCV","volume":"36","author":"Saab","year":"2016","journal-title":"Liver Int."},{"issue":"7893","key":"10.1016\/j.mam.2022.101159_bib293","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41586-021-04220-9","article-title":"Synthon-based ligand discovery in virtual libraries of over 11 billion compounds","volume":"601","author":"Sadybekov","year":"2022","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.mam.2022.101159_bib294","doi-asserted-by":"crossref","first-page":"7461","DOI":"10.1128\/jvi.69.12.7461-7471.1995","article-title":"The NS2 protein of hepatitis C virus is a transmembrane polypeptide","volume":"69","author":"Santolini","year":"1995","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.mam.2022.101159_bib295","doi-asserted-by":"crossref","first-page":"8295","DOI":"10.1002\/jcp.27715","article-title":"Expression of novel proteins by polyomaviruses and recent advances in the structural and functional features of agnoprotein of JC virus, BK virus, and simian virus 40","volume":"234","author":"Saribas","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"Suppl. 1","key":"10.1016\/j.mam.2022.101159_bib296","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0168-8278(12)60010-5","article-title":"Antiviral strategies in hepatitis C virus infection","volume":"56","author":"Sarrazin","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.mam.2022.101159_bib297","article-title":"S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters","author":"Sasaki","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.mam.2022.101159_bib298","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1110\/ps.036079.108","article-title":"Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir","volume":"17","author":"Saskov\u00e1","year":"2008","journal-title":"Protein Sci."},{"issue":"17","key":"10.1016\/j.mam.2022.101159_bib299","doi-asserted-by":"crossref","first-page":"8810","DOI":"10.1128\/JVI.00451-09","article-title":"Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir","volume":"83","author":"Saskov\u00e1","year":"2009","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib300","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0092-8674(88)90199-7","article-title":"Enzymatic activity of a synthetic 99 residue protein corresponding to the putative HIV-1 protease","volume":"54","author":"Schneider","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.mam.2022.101159_bib301","series-title":"PyMOL","author":"Schr\u00f6dinger","year":"2020"},{"issue":"18","key":"10.1016\/j.mam.2022.101159_bib302","doi-asserted-by":"crossref","first-page":"6612","DOI":"10.1073\/pnas.85.18.6612","article-title":"Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A","volume":"85","author":"Seelmeier","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.mam.2022.101159_bib303","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.1128\/AAC.00699-08","article-title":"Preclinical characteristics of the hepatitis C virus NS3\/4A protease inhibitor ITMN-191 (R7227)","volume":"52","author":"Seiwert","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl. 18","key":"10.1016\/j.mam.2022.101159_bib304","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1186\/s12859-020-03825-7","article-title":"Evolution of drug resistance in HIV protease","volume":"21","author":"Shah","year":"2020","journal-title":"BMC Bioinf."},{"issue":"12","key":"10.1016\/j.mam.2022.101159_bib305","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1128\/AAC.42.12.3218","article-title":"ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease","volume":"42","author":"Sham","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib306","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1038\/s41467-022-31210-w","article-title":"Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance","volume":"13","author":"Shaqra","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib307","doi-asserted-by":"crossref","first-page":"a006841","DOI":"10.1101\/cshperspect.a006841","article-title":"Origins of HIV and the AIDS pandemic","volume":"1","author":"Sharp","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"396","key":"10.1016\/j.mam.2022.101159_bib308","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib309","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1128\/JVI.75.4.1834-1841.2001","article-title":"Maintenance of the gag\/gag-pol ratio is important for human immunodeficiency virus type 1 RNA dimerization and viral infectivity","volume":"75","author":"Shehu-Xhilaga","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.mam.2022.101159_bib310","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.1016\/j.csbj.2021.11.016","article-title":"Novel dynamic residue network analysis approaches to study allosteric modulation: SARS-CoV-2 Mpro and its evolutionary mutations as a case study","volume":"19","author":"Sheik Amamuddy","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.mam.2022.101159_bib311","doi-asserted-by":"crossref","DOI":"10.1016\/j.tchem.2022.100033","article-title":"Total synthesis of antiviral drug, nirmatrelvir (PF-07321332)","volume":"4","author":"Shekhar","year":"2022","journal-title":"Tetrahedron Chem."},{"key":"10.1016\/j.mam.2022.101159_bib312","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcv.2015.02.005","article-title":"Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort","volume":"65","author":"Shepherd","year":"2015","journal-title":"J. Clin. Virol."},{"issue":"9","key":"10.1016\/j.mam.2022.101159_bib313","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.clinthera.2015.07.022","article-title":"Cobicistat: review of a pharmacokinetic enhancer for HIV infection","volume":"37","author":"Sherman","year":"2015","journal-title":"Clin. Therapeut."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib314","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1128\/AAC.40.1.110","article-title":"Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease","volume":"40","author":"Shetty","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.mam.2022.101159_bib315","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1128\/JVI.78.12.6657-6665.2004","article-title":"Herpesvirus protease inhibition by dimer disruption","volume":"78","author":"Shimba","year":"2004","journal-title":"J. Virol."},{"issue":"7835","key":"10.1016\/j.mam.2022.101159_bib316","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"issue":"7902","key":"10.1016\/j.mam.2022.101159_bib317","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-022-04442-5","article-title":"Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron","volume":"603","author":"Shuai","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.mam.2022.101159_bib318","series-title":"Classification of Human Viruses. Principles and Practice of Pediatric Infectious Diseases","author":"Siegel","year":"2018"},{"issue":"5","key":"10.1016\/j.mam.2022.101159_bib319","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41579-018-0120-2","article-title":"Prisoners of war - host adaptation and its constraints on virus evolution","volume":"17","author":"Simmonds","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"issue":"6","key":"10.1016\/j.mam.2022.101159_bib320","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s43440-020-00155-6","article-title":"Drug repurposing approach to fight COVID-19","volume":"72","author":"Singh","year":"2020","journal-title":"Pharmacol. Rep."},{"issue":"20","key":"10.1016\/j.mam.2022.101159_bib321","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1002\/cmdc.202100397","article-title":"Amino acid and peptide-based antiviral agents","volume":"16","author":"Skwarecki","year":"2021","journal-title":"ChemMedChem"},{"issue":"11","key":"10.1016\/j.mam.2022.101159_bib322","first-page":"1","article-title":"FDA triple header. Food and Drug Administration","volume":"9","author":"Smart","year":"1995","journal-title":"GMHC Treat. Iss."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib323","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.mam.2022.101159_bib324","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","article-title":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018","volume":"37","author":"Sorbo","year":"2018","journal-title":"Drug Resist. Updates"},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib325","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jac\/dkg079","article-title":"Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance","volume":"51","author":"Spira","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"issue":"25","key":"10.1016\/j.mam.2022.101159_bib326","doi-asserted-by":"crossref","first-page":"8899","DOI":"10.1021\/bi980313v","article-title":"Product inhibition of the hepatitis C virus NS3 protease","volume":"37","author":"Steink\u00fchler","year":"1998","journal-title":"Biochemistry"},{"issue":"11","key":"10.1016\/j.mam.2022.101159_bib327","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113437","article-title":"The anti-cancer properties of the HIV protease inhibitor nelfinavir","volume":"12","author":"Subeha","year":"2020","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.mam.2022.101159_bib328","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1128\/JVI.02306-12","article-title":"Efavirenz enhances HIV-1 gag processing at the plasma membrane through gag-pol dimerization","volume":"87","author":"Sudo","year":"2013","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.mam.2022.101159_bib329","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/AAC.00324-12","article-title":"MK-5172, a selective inhibitor of hepatitis C virus NS3\/4a protease with broad activity across genotypes and resistant variants","volume":"56","author":"Summa","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib330","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1179\/1973947812Y.0000000011","article-title":"Antitumour effects of a protease inhibitor, nelfinavir, in hepatocellular carcinoma cancer cells","volume":"24","author":"Sun","year":"2012","journal-title":"J. Chemother."},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib331","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/cid\/ciaa074","article-title":"Association between the use of antibiotics, antivirals, and hospitalizations among patients with laboratory-confirmed influenza","volume":"72","author":"Sutton","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.mam.2022.101159_bib332","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1128\/AAC.49.5.2015-2025.2005","article-title":"Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors","volume":"49","author":"Svicher","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.mam.2022.101159_bib333","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.02198-21","article-title":"The HIV-1 viral protease is activated during assembly and budding prior to particle release","volume":"96","author":"Tabler","year":"2022","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib334","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.str.2021.09.004","article-title":"MANORAA: a machine learning platform to guide protein-ligand design by anchors and influential distances","volume":"30","author":"Tanramluk","year":"2022","journal-title":"Structure"},{"issue":"16","key":"10.1016\/j.mam.2022.101159_bib335","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/j.bmcl.2019.03.037","article-title":"Discovery of the pan-genotypic hepatitis C virus NS3\/4A protease inhibitor voxilaprevir (GS-9857): a component of Vosevi","volume":"29","author":"Taylor","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib336","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/(SICI)1097-0282(1999)51:1<51::AID-BIP6>3.0.CO;2-U","article-title":"Structure-based discovery of Tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor","volume":"51","author":"Thaisrivongs","year":"1999","journal-title":"Biopolymers"},{"issue":"22","key":"10.1016\/j.mam.2022.101159_bib337","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1021\/jm960541s","article-title":"Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-Dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors","volume":"39","author":"Thaisrivongs","year":"1996","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib338","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1021\/ja00055a069","article-title":"3'-Tetrahydrofuranylglycine as a novel, unnatural amino acid surrogate for asparagine in the design of inhibitors of the HIV protease","volume":"115","author":"Thompson","year":"1993","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.mam.2022.101159_bib339","author":"Todosmedical"},{"issue":"Pt 5","key":"10.1016\/j.mam.2022.101159_bib340","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1099\/0022-1317-77-5-1065","article-title":"A central hydrophobic domain of the hepatitis C virus NS4A protein is necessary and sufficient for the activation of the NS3 protease","volume":"77","author":"Tomei","year":"1996","journal-title":"J. Gen. Virol."},{"issue":"6597","key":"10.1016\/j.mam.2022.101159_bib341","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/383272a0","article-title":"A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease","volume":"383","author":"Tong","year":"1996","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.mam.2022.101159_bib342","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/1860","article-title":"Conserved mode of peptidomimetic inhibition and substrate recognition of human cytomegalovirus protease","volume":"5","author":"Tong","year":"1998","journal-title":"Nat. Struct. Biol."},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib343","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.antiviral.2005.12.003","article-title":"Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034","volume":"70","author":"Tong","year":"2006","journal-title":"Antivir. Res."},{"issue":"6","key":"10.1016\/j.mam.2022.101159_bib344","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1128\/AAC.00135-10","article-title":"Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease","volume":"54","author":"Tong","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"515","key":"10.1016\/j.mam.2022.101159_bib345","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax5866","article-title":"Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia","volume":"11","author":"Toots","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.mam.2022.101159_bib346","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.trsl.2019.12.002","article-title":"Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model","volume":"218","author":"Toots","year":"2020","journal-title":"Transl. Res."},{"issue":"13","key":"10.1016\/j.mam.2022.101159_bib347","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.2146\/news110042","article-title":"Two drugs approved for chronic hepatitis C infection","volume":"68","author":"Traynor","year":"2011","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib348","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2147\/TCRM.S1709","article-title":"Combating HIV resistance - focus on darunavir","volume":"4","author":"Tremblay","year":"2008","journal-title":"Therapeut. Clin. Risk Manag."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib349","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12977-019-0479-9","article-title":"NNRTI-induced HIV-1 protease-mediated cytotoxicity induces rapid death of CD4 T cells during productive infection and latency reversal","volume":"16","author":"Trinit\u00e9","year":"2019","journal-title":"Retrovirology"},{"key":"10.1016\/j.mam.2022.101159_bib350","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.3389\/fimmu.2020.02130","article-title":"Viral emerging diseases: challenges in developing vaccination strategies","volume":"11","author":"Trovato","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib351","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/bcp.12403","article-title":"The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future","volume":"79","author":"Tseng","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.mam.2022.101159_bib352","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.769543","article-title":"Running with scissors: evolutionary conflicts between viral proteases and the host immune system","volume":"12","author":"Tsu","year":"2021","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.mam.2022.101159_bib353","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib354","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062448","article-title":"Nelfinavir inhibits intra-mitochondrial calcium influx and protects brain against hypoxic-ischemic injury in neonatal mice","volume":"8","author":"Utkina-Sosunova","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib355","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"V'Kovski","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib356","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1021\/jm00107a050","article-title":"L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor","volume":"34","author":"Vacca","year":"1991","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.mam.2022.101159_bib357","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1073\/pnas.91.9.4096","article-title":"L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor","volume":"91","author":"Vacca","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.mam.2022.101159_bib358","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00473-12","article-title":"Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans","volume":"3","author":"van Boheemen","year":"2012","journal-title":"mBio"},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib359","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/135965350200600401","article-title":"Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience","volume":"6","author":"van Heeswijk","year":"2001","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.mam.2022.101159_bib360","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern","volume":"198","author":"Vangeel","year":"2022","journal-title":"Antivir. Res."},{"issue":"5","key":"10.1016\/j.mam.2022.101159_bib361","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.tips.2012.03.012","article-title":"Discovery of boceprevir, a direct-acting NS3\/4A protease inhibitor for treatment of chronic hepatitis C infections","volume":"33","author":"Venkatraman","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"issue":"20","key":"10.1016\/j.mam.2022.101159_bib362","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.1021\/jm060325b","volume":"49","author":"Venkatraman","year":"2006","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib363","doi-asserted-by":"crossref","DOI":"10.1097\/COH.0000000000000527","article-title":"Current and future priorities for the development of optimal HIV drugs","volume":"14","author":"Vitoria","year":"2019","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib364","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1517\/14740338.4.3.403","article-title":"Safety of lopinavir\/ritonavir for the treatment of HIV-infection","volume":"4","author":"Vogel","year":"2005","journal-title":"Expet Opin. Drug Saf."},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib365","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1358\/dot.2008.44.2.1137107","article-title":"Atazanavir\/ritonavir: a review of its use in HIV therapy","volume":"44","author":"von Hentig","year":"2008","journal-title":"Drugs Today"},{"issue":"6535","key":"10.1016\/j.mam.2022.101159_bib366","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe1707","article-title":"CARD8 is an inflammasome sensor for HIV-1 protease activity","volume":"371","author":"Wang","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.mam.2022.101159_bib367","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101412","article-title":"Immunological approaches to HIV cure","volume":"51","author":"Ward","year":"2021","journal-title":"Semin. Immunol."},{"issue":"7594","key":"10.1016\/j.mam.2022.101159_bib368","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.mam.2022.101159_bib369","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0022-2836(02)01139-7","article-title":"Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains","volume":"324","author":"Weber","year":"2002","journal-title":"J. Mol. Biol."},{"issue":"8","key":"10.1016\/j.mam.2022.101159_bib370","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.4155\/fmc.15.44","article-title":"Highly resistant HIV-1 proteases and strategies for their inhibition","volume":"7","author":"Weber","year":"2015","journal-title":"Future Med. Chem."},{"issue":"11","key":"10.1016\/j.mam.2022.101159_bib371","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.3390\/pharmaceutics13111798","article-title":"Past HIV-1 medications and the current status of combined antiretroviral therapy options for HIV-1 patients","volume":"13","author":"Weichseldorfer","year":"2021","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib372","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/prot.25826","article-title":"Accessory mutations balance the marginal stability of the HIV-1 protease in drug resistance","volume":"88","author":"Weikl","year":"2020","journal-title":"Proteins"},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib373","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/07853890.2022.2034936","article-title":"Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19\uff1aa meta-analysis","volume":"54","author":"Wen","year":"2022","journal-title":"Ann. Med."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib374","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.antiviral.2009.10.003","article-title":"Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance","volume":"85","author":"Wensing","year":"2010","journal-title":"Antivir. Res."},{"key":"10.1016\/j.mam.2022.101159_bib375","author":"WHO"},{"issue":"7824","key":"10.1016\/j.mam.2022.101159_bib376","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2","volume":"585","author":"Williamson","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib377","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00003088-200645020-00002","article-title":"Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug","volume":"45","author":"Wire","year":"2006","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib378","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0166-3542(00)00139-X","article-title":"Genetic risks of antiviral nucleoside analogues--a survey","volume":"49","author":"Wutzler","year":"2001","journal-title":"Antivir. Res."},{"key":"10.1016\/j.mam.2022.101159_bib379","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejphar.2019.01.045","article-title":"Metformin combined with nelfinavir induces SIRT3\/mROS-dependent autophagy in human cervical cancer cells and xenograft in nude mice","volume":"848","author":"Xia","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.mam.2022.101159_bib380","article-title":"Evolutionary and structural insights about potential SARS-CoV-2 evasion of nirmatrelvir","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.mam.2022.101159_bib381","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1517\/14656566.2013.850074","article-title":"Simeprevir for the treatment of chronic hepatitis C","volume":"14","author":"You","year":"2013","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.mam.2022.101159_bib382","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114296","article-title":"Repurposing existing drugs for the treatment of COVID-19\/SARS-CoV-2 infection: a review describing drug mechanisms of action","volume":"183","author":"Yousefi","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.mam.2022.101159_bib383","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.antiviral.2011.05.016","article-title":"Lopinavir shows greater specificity than zinc finger ejecting compounds as a potential treatment for human papillomavirus-related lesions","volume":"91","author":"Zehbe","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.mam.2022.101159_bib384","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/bs.enz.2021.09.004","article-title":"Viral proteases: structure, mechanism and inhibition","volume":"50","author":"Zephyr","year":"2021","journal-title":"Enzymes"},{"issue":"9","key":"10.1016\/j.mam.2022.101159_bib385","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2022.167503","article-title":"Deciphering the molecular mechanism of HCV protease inhibitor fluorination as a general approach to avoid drug resistance","volume":"434","author":"Zephyr","year":"2022","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.mam.2022.101159_bib386","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"35","key":"10.1016\/j.mam.2022.101159_bib387","doi-asserted-by":"crossref","first-page":"8154","DOI":"10.1039\/C9SC00616H","article-title":"Bayesian semi-supervised learning for uncertainty-calibrated prediction of molecular properties and active learning","volume":"10","author":"Zhang","year":"2019","journal-title":"Chem. Sci."},{"issue":"9","key":"10.1016\/j.mam.2022.101159_bib388","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1128\/jvi.71.9.6662-6670.1997","article-title":"Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites","volume":"71","author":"Zhang","year":"1997","journal-title":"J. Virol."},{"issue":"6489","key":"10.1016\/j.mam.2022.101159_bib389","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.mam.2022.101159_bib390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009009","article-title":"Predominance of positive epistasis among drug resistance-associated mutations in HIV-1 protease","volume":"16","author":"Zhang","year":"2020","journal-title":"PLoS Genet."},{"key":"10.1016\/j.mam.2022.101159_bib391","article-title":"The efficacy and safety of Janus kinase inhibitors for patients with COVID-19: a living systematic review and meta-analysis","volume":"8","author":"Zhang","year":"2021","journal-title":"Front. Med."},{"issue":"21","key":"10.1016\/j.mam.2022.101159_bib392","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232113568","article-title":"Application of computational biology and artificial intelligence in drug design","volume":"23","author":"Zhang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mam.2022.101159_bib393","series-title":"Crystal Structure of SARS-CoV-2 Main Protease in Complex with Protease Inhibitor PF-07321332. Protein & Cell","author":"Zhao","year":"2021"},{"issue":"3","key":"10.1016\/j.mam.2022.101159_bib394","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jiab247","article-title":"\u03b2-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells","volume":"224","author":"Zhou","year":"2021","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.mam.2022.101159_bib395","series-title":"Nirmatrelvir Resistant SARS-CoV-2 Variants with High Fitness in Vitro","author":"Zhou","year":"2022"}],"container-title":["Molecular Aspects of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0098299722001042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0098299722001042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T18:21:55Z","timestamp":1758824515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0098299722001042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":395,"alternative-id":["S0098299722001042"],"URL":"https:\/\/doi.org\/10.1016\/j.mam.2022.101159","relation":{},"ISSN":["0098-2997"],"issn-type":[{"value":"0098-2997","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral proteases as therapeutic targets","name":"articletitle","label":"Article Title"},{"value":"Molecular Aspects of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mam.2022.101159","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101159"}}